Navigation Links
Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancer
Date:10/12/2010

An ongoing Phase-II trial investigating a new, targeted therapy for metastatic urothelial cancer has generated promising early results, Italian researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

Urothelial cancers affect the tissue lining the inner surfaces of the bladder and other parts of the urinary system. In cases of metastatic disease, median survival is approximately 12-15 months and there is a 10-15% chance of prolonging it by the use of standard chemotherapy regimens, particularly in otherwise healthy patients with good prognostic factors.

Those whose cancers relapse or do not respond to upfront therapy currently have few second-line treatment options and palliative care is the option in the majority of cases.

Dr Andrea Necchi from Fondazione IRCCS Istituto Nazionale dei Tumori of Milan and colleagues have begun a Phase-II trial using pazopanib in this setting. Pazopanib is a selective inhibitor of several signaling pathways that contribute to tumor growth and the development of new cancer-related blood vessels (angiogenesis).

So far, the researchers have enrolled 18 patients of a total of 41 planned. Each participant had metastatic urothelial cancer that had already failed to respond to at least one prior chemotherapy regimen. This means that investigators treated many patients who had already failed more than two chemotherapy regimens. Patients were administered 800mg of the drug once daily until their disease progressed or they experienced unacceptable toxicity.

"Thus far, four patients have seen their tumors shrink but, much more interestingly, the great majority of the patients --twelve out of eighteen-- saw their metastases begin to die," Dr Necchi said.

The death of these metastatic tumors, described formally as 'necrotic evolution', was observed by the researchers on monthly computed tomography and positron emission tomography scans.

"Considering this drug partly acts to prevent tumors recruiting the blood supplies they need to live and grow, necrotic evolution of metastases is not completely surprising," Dr Necchi said. "But this is the first time we have seen this phenomenon in so many cases of urothelial cancer. The challenge is to translate this kind of activity into a survival advantage."

"Of course we are only at the first step of this Phase-II trial and caution is needed when interpreting results," Dr Necchi said. "A longer follow-up time and greater sample size are needed before we can declare the study a success. However, for the first time in this disease we are generating interest among investigators and, particularly, of pharmaceutical industry."

The current trial is independent of the pharmaceutical industry, Dr Necchi noted. The sponsor is Fondazione IRCCS Istituto Nazionale dei Tumori of Milan. "The study shows that it is possible in Europe to promote independent research that focuses attention on challenging problematic matters, such as salvage therapy in urothelial cancer."

"These preliminary results underline the value of angiogenesis as a target in bladder cancer," commented Dr Joaquim Bellmunt, Section Chief, Solid Tumor Oncology at Hospital del Mar in Barcelona, Spain. "They add to results other groups have published recently using similar drugs to treat bladder cancer."


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
2. New Tool Shows Promise for Early Lung Cancer Screening
3. Womens race and class impact contraception recommendations, UCSF study shows
4. Bloodstream infection surveillance inconsistent between institutions, U-M study shows
5. Study shows faith-based interventions can encourage exercise in older African-American women
6. Study shows patient-specific vaccines for metastatic melanoma may induce durable complete regression
7. Unique gastroenterology procedure developed in adults shows promise in pediatrics
8. Novel Rheumatoid Arthritis Drug Shows Early Promise
9. Experimental Drug Shows Promise for Bone Marrow Disorder
10. Report shows federal poverty guidelines leave states seniors destitute
11. Study shows tranquil scenes have positive impact on brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Ga (PRWEB) , ... December 08, 2016 , ... ... as soon after surgery as possible. With this in mind, SIGVARIS has created ... (DVT or blood clot) during bed rest and provide the benefits of graduated ...
(Date:12/8/2016)... ... December 08, 2016 , ... Dickinson Insurance and Financial Services, ... Little Rock, has initiated a charity drive to provide support and funding to ... Senior Hunger, Arkansas ranks first in senior hunger statewide, third in child hunger, ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... serve communities in and around the greater Phoenix metropolitan region, is announcing a ... , The mission of the Homeless Youth Connection is to promote community awareness ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... financial consulting services to residential and commercial clients in the northern Alabama and ... for Nobis Works. , Since 1977, Nobis Works has built a network of ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... will have the unique opportunity to get hands-on experience in an emergency medical ... an immersive experience to gain invaluable, real-life medical skills that are critical success ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... KEY FINDINGS ... Patient warming and cooling devices offer several ... the risks of neurological disorders post cardiac arrests, rapid recovery ... systems can be segmented into convective warming system, surface warming ... stay at hospitals thus, lowering the healthcare costs by enhancing ...
(Date:12/8/2016)... 8, 2016 Global Interventional Radiology Market: ... global interventional radiology market analyzes the current and ... an elaborate executive summary, including a market snapshot ... sub-segments. The research is a combination of ... bulk of our research efforts along with information ...
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... of the market in 2016 and is expected to ... attributed to a large number of surgical procedures that ... largest share in the patient temperature management market.) Patient ... reducing loss of blood during surgeries, lowering the risks ...
Breaking Medicine Technology: